Ruben A. Mesa, MD, provides an update on the COMFORT-1 trial, which found that ruxolitinib has durable efficacy and long-term safety in patients with myelofibrosis.
COMFORT: Five-Year Outcomes of Ruxolitinib in Patients With Myelofibrosis
Recent Articles
Lawmakers Call for Investigation Into Federal Contributions to Remdesivir Development
A letter penned by Senator Debbie Stabenow (D-MI), of the Senate Committee on Oversight and Reform, and Representative Carolyn Maloney (D-NY), who chairs the...
Advocacy Groups Petition FDA to Limit Music During Drug Ads
Two advocacy groups, Knowledge Ecology International and the Center for Digital Democracy, filed a citizen’s petition with the FDA regarding the use of music...
FDA Grants Accelerated Approval to Tafasitamab-cxix for Relapsed/Refractory DLBCL
The FDA has granted accelerated approval to tafasitamab-cxix in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell...
NIH Awards $249 Million to Seven Companies for COVID-19 Diagnostic Development
The National Institutes of Health (NIH) has awarded $249 million in grants to seven medical diagnostic companies making new coronavirus diagnostic technology, in hopes...
How Well Do Antibody Tests Detect Mild COVID-19 Infection?
An Oxford University study of more than 9,000 health-care workers suggests antibody tests are not effective for people who had only a mild COVID-19...
Current Issue
August 2020 Volume 6, Issue 10
This issue looks at the rapid expansion of telemedicine, explores access to leukemia treatment in Brazil, and more.
